{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:25:00Z","timestamp":1786951500921,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019679","name":"Manisa Celal Bayar \u00dcniversitesi","doi-asserted-by":"publisher","award":["2014-169"],"award-info":[{"award-number":["2014-169"]}],"id":[{"id":"10.13039\/100019679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10735-026-10930-z","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:21:35Z","timestamp":1786072895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-dependent expression and nuclear localization of EZH2 in endometrial carcinogenesis: evidence from cell lines and human tissues"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-5869","authenticated-orcid":false,"given":"Oya","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-7319","authenticated-orcid":false,"given":"I\u015f\u0131l","family":"Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6597-6923","authenticated-orcid":false,"given":"Elgin Turkoz","family":"Uluer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-4302","authenticated-orcid":false,"given":"Muzaffer","family":"Sanc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-7584","authenticated-orcid":false,"given":"Gulden","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-5550","authenticated-orcid":false,"given":"Sevil","family":"Sayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1971-9720","authenticated-orcid":false,"given":"Sevin\u00e7","family":"\u0130nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"8","key":"10930_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15081042","volume":"15","author":"BI Abdul Wahab","year":"2025","unstructured":"Abdul Wahab BI, Shah SA, Mohd Arshad R, Alfian N, Tan GC, Wong YP (2025) Immunoexpressions of PD-L1 and EZH2 in endometrial carcinoma: associations with clinicopathological parameters. Diagnostics 15(8):1042. https:\/\/doi.org\/10.3390\/diagnostics15081042","journal-title":"Diagnostics"},{"key":"10930_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2022.11.012","volume":"168","author":"\u00c5 \u00c5kesson","year":"2023","unstructured":"\u00c5kesson \u00c5, Adok C, Dahm-K\u00e4hler P (2023) Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study. Gynecol Oncol 168:127\u2013134. https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10930_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/gyno.2000.5955","volume":"79","author":"CA Amezcua","year":"2000","unstructured":"Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W (2000) Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 79(2):169\u2013176. https:\/\/doi.org\/10.1006\/gyno.2000.5955","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10930_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/jcm14041385","volume":"14","author":"MB Anca-Stanciu","year":"2025","unstructured":"Anca-Stanciu MB, Manu A, Olinca MV, Coroleuc\u0103 C, Comanda\u0219u DE, Coroleuca CA, Maier C, Bratila E (2025) Comprehensive review of endometrial cancer: new molecular and FIGO classification and recent treatment changes. J Clin Med 14(4):1385. https:\/\/doi.org\/10.3390\/jcm14041385","journal-title":"J Clin Med"},{"issue":"3","key":"10930_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.47162\/RJME.61.3.09","volume":"61","author":"I Aydemir","year":"2020","unstructured":"Aydemir I, Turkoz Uluer E, Korkmaz O, Tuglu MI, Inan S (2020) Adjuvant effects of chemotherapeutics and metformin on MFE-319 endometrial carcinoma cell line. Rom J Morphol Embryol 61(3):707\u2013714. https:\/\/doi.org\/10.47162\/RJME.61.3.09","journal-title":"Rom J Morphol Embryol"},{"issue":"1","key":"10930_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/ol.2023.13902","volume":"26","author":"YK Bai","year":"2023","unstructured":"Bai YK, Sun J, Wang YS, Zheng N, Xu QL, Wang Y (2023) The clinicopathological and prognostic significances of EZH2 expression in urological cancers: a meta-analysis and bioinformatics analysis. Oncol Lett 26(1):315. https:\/\/doi.org\/10.3892\/ol.2023.13902","journal-title":"Oncol Lett"},{"issue":"5","key":"10930_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.fertnstert.2005.10.072","volume":"85","author":"H Browne","year":"2006","unstructured":"Browne H, Taylor H (2006) HOXA10 expression in ectopic endometrial tissue. Fertil Steril 85(5):1386\u20131390. https:\/\/doi.org\/10.1016\/j.fertnstert.2005.10.072","journal-title":"Fertil Steril"},{"key":"10930_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.108070","volume":"154","author":"R Cao","year":"2025","unstructured":"Cao R, Ni J, Zhang X, Qi M, Zhang Z, Liu Z, Chen G (2025) Recent advances in enhancer of zeste homolog 2 inhibitors: structural insights and therapeutic applications. Bioorg Chem 154:108070. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108070","journal-title":"Bioorg Chem"},{"issue":"1","key":"10930_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64338-4","volume":"14","author":"T Colon","year":"2024","unstructured":"Colon T, Kou Z, Choi BH, Tran F, Zheng E, Dai W (2024) Enzyme-independent role of EZH2 in regulating cell cycle progression via the SKP2-KIP\/CIP pathway. Sci Rep 14(1):13389. https:\/\/doi.org\/10.1038\/s41598-024-64338-4","journal-title":"Sci Rep"},{"key":"10930_CR10","doi-asserted-by":"crossref","unstructured":"Eskander RN, Schram AM, et al., (2024) Clinical activity of tazemetostat, an EZH2 inhibitor, in patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014). Presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women\u2019s Cancer; March 16\u201318; San Diego, CA, USA. Late-Breaking Abstract.","DOI":"10.1016\/j.ygyno.2024.07.086"},{"key":"10930_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.600514","volume":"10","author":"B Gao","year":"2021","unstructured":"Gao B, Liu X, Li Z, Zhao L, Pan Y (2021) Overexpression of EZH2\/NSD2 histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in triple-negative breast cancer. Front Oncol 10:600514. https:\/\/doi.org\/10.3389\/fonc.2020.600514","journal-title":"Front Oncol"},{"issue":"5","key":"10930_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102852","volume":"54","author":"N Gautam","year":"2023","unstructured":"Gautam N, Kaur S, Kashyap S (2023) EZH2 expression and survival for ER+\/tamoxifen treated breast cancer patients with rs2302427 C>G: a novel prognostic and risk predictive biomarker. Arch Med Res 54(5):102852. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102852","journal-title":"Arch Med Res"},{"issue":"24","key":"10930_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29245817","volume":"29","author":"MS Gilardini Montani","year":"2024","unstructured":"Gilardini Montani MS, Benedetti R, Cirone M (2024) Targeting EZH2 in cancer: mechanisms, pathways, and therapeutic potential. Molecules 29(24):5817. https:\/\/doi.org\/10.3390\/molecules29245817","journal-title":"Molecules"},{"key":"10930_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820980781","volume":"19","author":"Y Guo","year":"2020","unstructured":"Guo Y, Zhao N, Zhou J, Dong J, Wang X (2020) Sirtuin 2 in endometrial cancer: a potential regulator for cell proliferation, apoptosis and RAS\/ERK pathway. Technol Cancer Res Treat 19:1533033820980781. https:\/\/doi.org\/10.1177\/1533033820980781","journal-title":"Technol Cancer Res Treat"},{"key":"10930_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104972","volume":"100","author":"Y Guo","year":"2024","unstructured":"Guo Y, Cheng R, Wang Y, Gonzalez ME, Zhang H, Liu Y, Kleer CG, Xue L (2024a) Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic. EBioMedicine 100:104972. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104972","journal-title":"EBioMedicine"},{"key":"10930_CR16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86168","volume":"13","author":"P Guo","year":"2024","unstructured":"Guo P, Lim RC, Rajawasam K, Trinh T, Sun H, Zhang H (2024b) A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis. Elife 13:e86168. https:\/\/doi.org\/10.7554\/eLife.86168","journal-title":"Elife"},{"issue":"7","key":"10930_CR17","doi-asserted-by":"publisher","first-page":"7949","DOI":"10.1007\/s00210-025-03883-9","volume":"398","author":"CY Hsu","year":"2025","unstructured":"Hsu CY, Mohammed AN, Hjazi A, Uthirapathy S, Renuka JS, Singh A, Thyagarajan RS, Hulail HM (2025) Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect. Naunyn Schmiedebergs Arch Pharmacol 398(7):7949\u20137970. https:\/\/doi.org\/10.1007\/s00210-025-03883-9","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10930_CR18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/cas.14840","volume":"112","author":"J Huang","year":"2021","unstructured":"Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M, Zhao T (2021) The noncanonical role of EZH2 in cancer. Cancer Sci 112(4):1376\u20131382. https:\/\/doi.org\/10.1111\/cas.14840","journal-title":"Cancer Sci"},{"key":"10930_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216706","volume":"586","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S (2024) EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett 586:216706. https:\/\/doi.org\/10.1016\/j.canlet.2024.216706","journal-title":"Cancer Lett"},{"key":"10930_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1303918","volume":"14","author":"F Li","year":"2024","unstructured":"Li F, Wang P, Ye J, Xie G, Yang J, Liu W (2024) Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis. Front Oncol 14:1303918. https:\/\/doi.org\/10.3389\/fonc.2024.1303918","journal-title":"Front Oncol"},{"issue":"6","key":"10930_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q (2023) The roles of EZH2 in cancer and its inhibitors. Med Oncol 40(6):167. https:\/\/doi.org\/10.1007\/s12032-023-02025-6","journal-title":"Med Oncol"},{"issue":"1","key":"10930_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad001","volume":"7","author":"L Liu","year":"2023","unstructured":"Liu L, Habeshian TS, Zhang J, Peeri NC, Du M, De Vivo I, Setiawan VW (2023) Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. JNCI Cancer Spectr 7(1):pkad001. https:\/\/doi.org\/10.1093\/jncics\/pkad001","journal-title":"JNCI Cancer Spectr"},{"issue":"2A","key":"10930_CR23","first-page":"1075","volume":"23","author":"I Mylonas","year":"2003","unstructured":"Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K (2003) Immunohistochemical expression of the tumour marker CA-125 in normal, hyperplastic and malignant endometrial tissue. Anticancer Res 23(2A):1075\u20131080","journal-title":"Anticancer Res"},{"key":"10930_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s42047-024-00164-2","volume":"7","author":"J Nagel","year":"2024","unstructured":"Nagel J, Paschoalini RB, Barreto PSD, Credidio CH, Paulino E, Del Pilar Estevez-Diz M (2024) Predictive biomarkers in endometrial carcinomas: a review of their relevance in daily anatomic pathology. Surg Exp Pathol 7:21. https:\/\/doi.org\/10.1186\/s42047-024-00164-2","journal-title":"Surg Exp Pathol"},{"issue":"15","key":"10930_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14151686","volume":"14","author":"A Nienhaus","year":"2024","unstructured":"Nienhaus A, Rajakulendran R, Bernad E (2024) A 10-year retrospective cohort study of endometrial cancer outcomes and associations with lymphovascular invasion: a single-center study from Germany. Diagnostics 14(15):1686. https:\/\/doi.org\/10.3390\/diagnostics14151686","journal-title":"Diagnostics"},{"issue":"4","key":"10930_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/cge.14576","volume":"106","author":"M Sabour-Takanlou","year":"2024","unstructured":"Sabour-Takanlou M, Sabour-Takanlou L, Biray-Avci C (2024) EZH2-associated tumor malignancy: a prominent target for cancer treatment. Clin Genet 106(4):377\u2013385. https:\/\/doi.org\/10.1111\/cge.14576","journal-title":"Clin Genet"},{"issue":"20","key":"10930_CR27","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1016\/j.molcel.2024.08.025","volume":"84","author":"PV Sauer","year":"2024","unstructured":"Sauer PV, Pavlenko E, Cookis T, Zirden LC, Renn J, Singhal A, Hunold P, Hoehne-Wiechmann MN, van Ray O, Kaschani F, Kaiser M, H\u00e4nsel-Hertsch R, Sanbonmatsu KY, Nogales E, Poepsel S (2024) Activation of automethylated PRC2 by dimerization on chromatin. Mol Cell 84(20):3885-3898.e8. https:\/\/doi.org\/10.1016\/j.molcel.2024.08.025","journal-title":"Mol Cell"},{"issue":"4","key":"10930_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00004347-199710000-00009","volume":"16","author":"T Shiozawa","year":"1997","unstructured":"Shiozawa T, Xin L, Nikaido T, Fujii S (1997) Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int J Gynecol Pathol 16(4):348\u2013353. https:\/\/doi.org\/10.1097\/00004347-199710000-00009","journal-title":"Int J Gynecol Pathol"},{"issue":"19","key":"10930_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193111","volume":"17","author":"S Verma","year":"2025","unstructured":"Verma S, Goyal N, Goyal S, Kaur P, Gupta S (2025) EZH2 dysregulation and its oncogenic role in human cancers. Cancers 17(19):3111. https:\/\/doi.org\/10.3390\/cancers17193111","journal-title":"Cancers"},{"key":"10930_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241306026","volume":"17","author":"M Wozniak","year":"2025","unstructured":"Wozniak M, Czyz M (2025) Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities. Ther Adv Med Oncol 17:17588359241306026. https:\/\/doi.org\/10.1177\/17588359241306026","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10930_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111999","volume":"16","author":"H Yamashita","year":"2024","unstructured":"Yamashita H, Nakayama K, Kanno K, Ishibashi T, Ishikawa M, Iida K, Razia S, Kiyono T, Kyo S (2024) Evaluation of ARID1A as a potential biomarker for predicting response to immune checkpoint inhibitors in patients with endometrial cancer. Cancers 16(11):1999. https:\/\/doi.org\/10.3390\/cancers16111999","journal-title":"Cancers"},{"issue":"2","key":"10930_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cancers15020425","volume":"15","author":"W Yu","year":"2023","unstructured":"Yu W, Liu N, Song X, Chen L, Wang M, Xiao G, Li T, Wang Z, Zhang Y (2023) EZH2: an accomplice of gastric cancer. Cancers 15(2):425. https:\/\/doi.org\/10.3390\/cancers15020425","journal-title":"Cancers"},{"key":"10930_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233953","volume":"13","author":"SM Zimmerman","year":"2023","unstructured":"Zimmerman SM, Lin PN, Souroullas GP (2023) Non-canonical functions of EZH2 in cancer. Front Oncol 13:1233953. https:\/\/doi.org\/10.3389\/fonc.2023.1233953","journal-title":"Front Oncol"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-10930-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-026-10930-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-10930-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:48:41Z","timestamp":1786949321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10735-026-10930-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10930"],"URL":"https:\/\/doi.org\/10.1007\/s10735-026-10930-z","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1567-2387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared that there is no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Local Ethics Committee of Manisa Celal Bayar University Faculty of Medicine (Approval number: 20478486\u2013370).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for individual informed consent was waived by the Institutional Ethics Committee because of the retrospective nature of the study and the use of archived anonymized specimens.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"262"}}